Home
ABVC
ABVC News

Latest ABVC BioPharma Inc. (ABVC) News on February 23, 2025

ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025

NewMediaWire

3 days ago

ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025

Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion

NewMediaWire

11 days ago

Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion

ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference

NewMediaWire

a month ago

ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference

ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market

NewMediaWire

a month ago

ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market

AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees

NewMediaWire

a month ago

AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees

ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement

NewMediaWire

a month ago

ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement

ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products

NewMediaWire

2 months ago

ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products

ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market

NewMediaWire

2 months ago

ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

GlobeNewswire

2 months ago

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

GlobeNewswire

2 months ago

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

GlobeNewswire

3 months ago

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

GlobeNewswire

4 months ago

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

GlobeNewswire

6 months ago

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI

NewMediaWire

7 months ago

ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI

ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals

NewMediaWire

8 months ago

ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals

ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market

NewMediaWire

8 months ago

ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market

ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue

NewMediaWire

8 months ago

ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue

Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M

NewMediaWire

9 months ago

Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M

ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M

NewMediaWire

9 months ago

ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M

Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M

NewMediaWire

9 months ago

Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M

Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

NewMediaWire

9 months ago

Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

GlobeNewswire

10 months ago

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

GlobeNewswire

10 months ago

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

NewMediaWire

10 months ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

NewMediaWire

a year ago

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars

GlobeNewswire

a year ago

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

NewMediaWire

a year ago

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

NewMediaWire

a year ago

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

NewMediaWire

a year ago

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

NewMediaWire

a year ago

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

GlobeNewswire

a year ago

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

NewMediaWire

a year ago

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

20 Countries With The Highest Number of Drug Trafficking in the World

Insider Monkey

a year ago

20 Countries With The Highest Number of Drug Trafficking in the World

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

a year ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement

PR Newswire

a year ago

Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement

2024 Marks a New Era Of Pharmaceutical Innovation

Benzinga

a year ago

2024 Marks a New Era Of Pharmaceutical Innovation

Ascendiant Capital Markets Maintains Buy Rating for Knightscope Raises Per Share Price Target to $4.00

Business Wire

a year ago

Ascendiant Capital Markets Maintains Buy Rating for Knightscope Raises Per Share Price Target to $4.00

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

GlobeNewswire

a year ago

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

How Vistagen (VTGN) Stock Stands Out in a Strong Industry

Zacks

a year ago

How Vistagen (VTGN) Stock Stands Out in a Strong Industry

Investors Sour on EV Charging Companies

The Wall Street Journal

a year ago

Investors Sour on EV Charging Companies

BiggerPockets Podcast Network Moves to Cumulus

GlobeNewswire

a year ago

BiggerPockets Podcast Network Moves to Cumulus

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

GlobeNewswire

a year ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Unlocking the Future: Aware Partners with Avanza Solutions to Extend World Class Biometric Authentication Across Middle East, Asia and Africa

GlobeNewswire

a year ago

Unlocking the Future: Aware Partners with Avanza Solutions to Extend World Class Biometric Authentication Across Middle East, Asia and Africa

Yoshitsu Co., Ltd to Report First Six Months of Fiscal Year 2024 Financial Results on Friday, December 22, 2023

GlobeNewswire

a year ago

Yoshitsu Co., Ltd to Report First Six Months of Fiscal Year 2024 Financial Results on Friday, December 22, 2023

What Does Viemed Healthcare, Inc.'s (TSE:VMD) Share Price Indicate?

Simply Wall St.

a year ago

What Does Viemed Healthcare, Inc.'s (TSE:VMD) Share Price Indicate?

Anixa Biosciences to Present at Biotech Showcase 2024

PR Newswire

a year ago

Anixa Biosciences to Present at Biotech Showcase 2024

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

GlobeNewswire

a year ago

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Hedge Funds are Betting on These 14 Sliding Stocks

Insider Monkey

a year ago

Hedge Funds are Betting on These 14 Sliding Stocks

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials

GlobeNewswire

a year ago

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials

Gaia Appoints James Colquhoun as CEO and Launches New AI Powered Search

GlobeNewswire

a year ago

Gaia Appoints James Colquhoun as CEO and Launches New AI Powered Search

First Guaranty Bancshares, Inc. Declares 122nd Consecutive Quarterly Cash Dividend to Shareholders

GlobeNewswire

a year ago

First Guaranty Bancshares, Inc. Declares 122nd Consecutive Quarterly Cash Dividend to Shareholders

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

GlobeNewswire

a year ago

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Hanryu Holdings Reports Third Quarter and First Nine Month 2023 Financial Results

ACCESSWIRE

a year ago

Hanryu Holdings Reports Third Quarter and First Nine Month 2023 Financial Results

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

GlobeNewswire

a year ago

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

GlobeNewswire

a year ago

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript

Kolibri Global Energy Announces Third Quarter 2023 Net Income of US$2.3 Million and Adjusted EBITDA of US$9.5 Million

Business Wire

a year ago

Kolibri Global Energy Announces Third Quarter 2023 Net Income of US$2.3 Million and Adjusted EBITDA of US$9.5 Million

The Eastern Company (NASDAQ:EML) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

The Eastern Company (NASDAQ:EML) Q3 2023 Earnings Call Transcript

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript

Business Wire

a year ago

GrowGeneration Reports Third Quarter 2023 Financial Results

3 Meme Stocks to Sell Immediately

InvestorPlace

a year ago

3 Meme Stocks to Sell Immediately

Thomson Reuters StreetEvents

a year ago

Q3 2023 Corvus Pharmaceuticals Inc Earnings Call

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

GlobeNewswire

a year ago

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Energy Vault Announces Five Additional EVx™ Gravity Energy Storage System Deployments in China

Business Wire

a year ago

Energy Vault Announces Five Additional EVx™ Gravity Energy Storage System Deployments in China

Associated Press Finance

a year ago

Beasley: Q3 Earnings Snapshot

InterCure Wins Cannolam Arbitration Proceeding

GlobeNewswire

a year ago

InterCure Wins Cannolam Arbitration Proceeding

Share on Social Networks: